Sandbox Reserved 1769: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 37: Line 37:


Insight into NTCP's structure and function has implications for therapeutic treatment of HBV/HDV infection. The overlap in NTCP binding sites for bile salts and HBV/HDV viruses presents therapeutic issues in blocking HBV/HDV infection without inhibiting normal bile acid uptake. For example, [https://en.wikipedia.org/wiki/Bulevirtide mycludex B] is a current first-class inhibitor of HDV infection, but suffers the drawback of hindering bile acid uptake.<ref name="Park"/> Potentially overcoming this, the inhibitory effect of antibody Nb87 on myr-preS1 binding shows potential for therapeutics that stabilize NTCP inward facing state as an [https://en.wikipedia.org/wiki/Allosteric_regulation allosteric inhibitor] of viral cell entry. <Ref name="Zhang" /> With Nb87 bound, HBV/HDV infection was reduced, although transport of bile salts persisted. Another study has identified a [https://en.wikipedia.org/wiki/Ciclosporin ciclosporin] derivative that has the capability to prevent HBV binding while still allowing NTCP to transport bile salts. <Ref name="Shimura"> Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol. 2017 Apr;66(4):685-692. doi: 10.1016/j.jhep.2016.11.009. [https://dx.doi.org/10.1016/j.jhep.2016.11.009 DOI: 10.1016/j.jhep.2016.11.009]. </Ref> This small molecule is the first to successfully prevent infection against multiple HBV genotypes without hindering normal NTCP activity.<ref name="Shimura"/> Future studies will work to identify more effective and safe ways to prevent infection without hindering normal bile acid uptake.
Insight into NTCP's structure and function has implications for therapeutic treatment of HBV/HDV infection. The overlap in NTCP binding sites for bile salts and HBV/HDV viruses presents therapeutic issues in blocking HBV/HDV infection without inhibiting normal bile acid uptake. For example, [https://en.wikipedia.org/wiki/Bulevirtide mycludex B] is a current first-class inhibitor of HDV infection, but suffers the drawback of hindering bile acid uptake.<ref name="Park"/> Potentially overcoming this, the inhibitory effect of antibody Nb87 on myr-preS1 binding shows potential for therapeutics that stabilize NTCP inward facing state as an [https://en.wikipedia.org/wiki/Allosteric_regulation allosteric inhibitor] of viral cell entry. <Ref name="Zhang" /> With Nb87 bound, HBV/HDV infection was reduced, although transport of bile salts persisted. Another study has identified a [https://en.wikipedia.org/wiki/Ciclosporin ciclosporin] derivative that has the capability to prevent HBV binding while still allowing NTCP to transport bile salts. <Ref name="Shimura"> Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol. 2017 Apr;66(4):685-692. doi: 10.1016/j.jhep.2016.11.009. [https://dx.doi.org/10.1016/j.jhep.2016.11.009 DOI: 10.1016/j.jhep.2016.11.009]. </Ref> This small molecule is the first to successfully prevent infection against multiple HBV genotypes without hindering normal NTCP activity.<ref name="Shimura"/> Future studies will work to identify more effective and safe ways to prevent infection without hindering normal bile acid uptake.


</StructureSection>
</StructureSection>
Retrieved from "https://proteopedia.org/Sandbox_Reserved_1769"